All In Biotech

Drug Trial Radar · NCT05214768

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Subjects With Eosinophilic Gastroenteritis

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

48

Actual

Start

Mar 4, 2022

Primary completion

Jul 2, 2024

Study completion Aug 22, 2025

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of CC-93538 in adult and adolescent participants with eosinophilic gastroenteritis.

Conditions

  • Eosinophilic Gastroenteritis

Interventions

  • CC-93538Drug

    Specified dose on specified days

  • PlaceboDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Number of Peak Eosinophils (Eos) Count Per High-power Field (Hpf) in Gastrointestinal (GI) BiopsiesTime frame: Baseline and Week 16

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 010

    Akita, Japan

  • Local Institution - 017

    Hirosaki, Japan

  • Local Institution - 015

    Hiroshima, Japan

  • Local Institution - 020

    Kitakyushu, Japan

  • Local Institution - 004

    Kobe, Japan

  • Local Institution - 011

    Maebashi, Japan

  • Local Institution - 013

    Nagaoka, Japan

  • Local Institution - 006

    Nagoya, Japan

  • Local Institution - 021

    Nagoya, Japan

  • Local Institution - 008

    Niigata, Japan

  • Local Institution - 012

    Ōgaki, Japan

  • Local Institution - 005

    Shibukawa, Japan

  • Local Institution - 019

    Tokyo, Japan

  • Local Institution - 003

    Yamagata, Japan

  • Local Institution - 024

    Gifu, Gifu, Japan

  • Local Institution - 022

    Himeji-shi, Hyōgo, Japan

  • Local Institution - 009

    Nishinomiya, Hyōgo, Japan

  • Local Institution - 018

    Kagoshima, Kagoshima-ken, Japan

  • Local Institution - 0025

    Tsu, Mie-ken, Japan

  • Local Institution - 025

    Tsu, Mie-ken, Japan

  • Local Institution - 023

    Sendai, Miyagi, Japan

  • Local Institution - 016

    Nagasaki, Nagasaki, Japan

  • Local Institution - 002

    Osaka, Osaka, Japan

  • Local Institution - 007

    Bunkyo-ku, Tokyo, Japan

  • Local Institution - 001

    Setagaya-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.